Clinical trials in recurrent ovarian cancer

Michael Friedlander, Edward Trimble, Anna Tinker, David S Alberts, Elisabeth Avall-Lundqvist, Mark Brady, Philipp Harter, Sandro Pignata, Eric Pujade-Lauraine, Jalid Sehouli, Ignace Vergote, Philip Beale, Rudd Bekkers, Paula Calvert, Lawrence Copeland, Ros Glasspool, Antonio Gonzalez-Martin, Dionysis Katsaros, Jae Won Kim, Brigitte MillerDiane Provencher, Lawrence Rubinstein, Mostafa Atri, Alain Zeimet, Monica Bacon, Henry Kitchener, Gavin C E Stuart

Research output: Contribution to journalArticle

119 Citations (Scopus)

Abstract

The 4th Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup was held in Vancouver, Canada, in June 2010. Representatives of 23 cooperative research groups studying gynecologic cancers gathered to establish international consensus on issues critical to the conduct of large randomized trials. Group C, 1 of the 3 discussion groups, examined recurrent ovarian cancer, and we report the consensus reached regarding 4 questions. These included the following: (1) What is the role of cytoreductive surgery for recurrent ovarian cancer? (2) How do we define distinct patient populations in need of specific therapeutic approaches? (3) Should end points for trials with recurrent disease vary from those of first-line trials? (4) Is CA-125 progression alone sufficient for entry/eligibility into clinical trials?

Original languageEnglish (US)
Pages (from-to)771-775
Number of pages5
JournalInternational Journal of Gynecological Cancer
Volume21
Issue number4
DOIs
StatePublished - May 2011
Externally publishedYes

Fingerprint

Ovarian Neoplasms
Clinical Trials
Canada
Neoplasms
Research
Population
Therapeutics

Keywords

  • Clinical trials
  • Ovarian cancer
  • Recurrent

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Oncology

Cite this

Friedlander, M., Trimble, E., Tinker, A., Alberts, D. S., Avall-Lundqvist, E., Brady, M., ... Stuart, G. C. E. (2011). Clinical trials in recurrent ovarian cancer. International Journal of Gynecological Cancer, 21(4), 771-775. https://doi.org/10.1097/IGC.0b013e31821bb8aa

Clinical trials in recurrent ovarian cancer. / Friedlander, Michael; Trimble, Edward; Tinker, Anna; Alberts, David S; Avall-Lundqvist, Elisabeth; Brady, Mark; Harter, Philipp; Pignata, Sandro; Pujade-Lauraine, Eric; Sehouli, Jalid; Vergote, Ignace; Beale, Philip; Bekkers, Rudd; Calvert, Paula; Copeland, Lawrence; Glasspool, Ros; Gonzalez-Martin, Antonio; Katsaros, Dionysis; Kim, Jae Won; Miller, Brigitte; Provencher, Diane; Rubinstein, Lawrence; Atri, Mostafa; Zeimet, Alain; Bacon, Monica; Kitchener, Henry; Stuart, Gavin C E.

In: International Journal of Gynecological Cancer, Vol. 21, No. 4, 05.2011, p. 771-775.

Research output: Contribution to journalArticle

Friedlander, M, Trimble, E, Tinker, A, Alberts, DS, Avall-Lundqvist, E, Brady, M, Harter, P, Pignata, S, Pujade-Lauraine, E, Sehouli, J, Vergote, I, Beale, P, Bekkers, R, Calvert, P, Copeland, L, Glasspool, R, Gonzalez-Martin, A, Katsaros, D, Kim, JW, Miller, B, Provencher, D, Rubinstein, L, Atri, M, Zeimet, A, Bacon, M, Kitchener, H & Stuart, GCE 2011, 'Clinical trials in recurrent ovarian cancer', International Journal of Gynecological Cancer, vol. 21, no. 4, pp. 771-775. https://doi.org/10.1097/IGC.0b013e31821bb8aa
Friedlander M, Trimble E, Tinker A, Alberts DS, Avall-Lundqvist E, Brady M et al. Clinical trials in recurrent ovarian cancer. International Journal of Gynecological Cancer. 2011 May;21(4):771-775. https://doi.org/10.1097/IGC.0b013e31821bb8aa
Friedlander, Michael ; Trimble, Edward ; Tinker, Anna ; Alberts, David S ; Avall-Lundqvist, Elisabeth ; Brady, Mark ; Harter, Philipp ; Pignata, Sandro ; Pujade-Lauraine, Eric ; Sehouli, Jalid ; Vergote, Ignace ; Beale, Philip ; Bekkers, Rudd ; Calvert, Paula ; Copeland, Lawrence ; Glasspool, Ros ; Gonzalez-Martin, Antonio ; Katsaros, Dionysis ; Kim, Jae Won ; Miller, Brigitte ; Provencher, Diane ; Rubinstein, Lawrence ; Atri, Mostafa ; Zeimet, Alain ; Bacon, Monica ; Kitchener, Henry ; Stuart, Gavin C E. / Clinical trials in recurrent ovarian cancer. In: International Journal of Gynecological Cancer. 2011 ; Vol. 21, No. 4. pp. 771-775.
@article{c66f3e716fb74eeb908aff372b16706b,
title = "Clinical trials in recurrent ovarian cancer",
abstract = "The 4th Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup was held in Vancouver, Canada, in June 2010. Representatives of 23 cooperative research groups studying gynecologic cancers gathered to establish international consensus on issues critical to the conduct of large randomized trials. Group C, 1 of the 3 discussion groups, examined recurrent ovarian cancer, and we report the consensus reached regarding 4 questions. These included the following: (1) What is the role of cytoreductive surgery for recurrent ovarian cancer? (2) How do we define distinct patient populations in need of specific therapeutic approaches? (3) Should end points for trials with recurrent disease vary from those of first-line trials? (4) Is CA-125 progression alone sufficient for entry/eligibility into clinical trials?",
keywords = "Clinical trials, Ovarian cancer, Recurrent",
author = "Michael Friedlander and Edward Trimble and Anna Tinker and Alberts, {David S} and Elisabeth Avall-Lundqvist and Mark Brady and Philipp Harter and Sandro Pignata and Eric Pujade-Lauraine and Jalid Sehouli and Ignace Vergote and Philip Beale and Rudd Bekkers and Paula Calvert and Lawrence Copeland and Ros Glasspool and Antonio Gonzalez-Martin and Dionysis Katsaros and Kim, {Jae Won} and Brigitte Miller and Diane Provencher and Lawrence Rubinstein and Mostafa Atri and Alain Zeimet and Monica Bacon and Henry Kitchener and Stuart, {Gavin C E}",
year = "2011",
month = "5",
doi = "10.1097/IGC.0b013e31821bb8aa",
language = "English (US)",
volume = "21",
pages = "771--775",
journal = "International Journal of Gynecological Cancer",
issn = "1048-891X",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Clinical trials in recurrent ovarian cancer

AU - Friedlander, Michael

AU - Trimble, Edward

AU - Tinker, Anna

AU - Alberts, David S

AU - Avall-Lundqvist, Elisabeth

AU - Brady, Mark

AU - Harter, Philipp

AU - Pignata, Sandro

AU - Pujade-Lauraine, Eric

AU - Sehouli, Jalid

AU - Vergote, Ignace

AU - Beale, Philip

AU - Bekkers, Rudd

AU - Calvert, Paula

AU - Copeland, Lawrence

AU - Glasspool, Ros

AU - Gonzalez-Martin, Antonio

AU - Katsaros, Dionysis

AU - Kim, Jae Won

AU - Miller, Brigitte

AU - Provencher, Diane

AU - Rubinstein, Lawrence

AU - Atri, Mostafa

AU - Zeimet, Alain

AU - Bacon, Monica

AU - Kitchener, Henry

AU - Stuart, Gavin C E

PY - 2011/5

Y1 - 2011/5

N2 - The 4th Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup was held in Vancouver, Canada, in June 2010. Representatives of 23 cooperative research groups studying gynecologic cancers gathered to establish international consensus on issues critical to the conduct of large randomized trials. Group C, 1 of the 3 discussion groups, examined recurrent ovarian cancer, and we report the consensus reached regarding 4 questions. These included the following: (1) What is the role of cytoreductive surgery for recurrent ovarian cancer? (2) How do we define distinct patient populations in need of specific therapeutic approaches? (3) Should end points for trials with recurrent disease vary from those of first-line trials? (4) Is CA-125 progression alone sufficient for entry/eligibility into clinical trials?

AB - The 4th Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup was held in Vancouver, Canada, in June 2010. Representatives of 23 cooperative research groups studying gynecologic cancers gathered to establish international consensus on issues critical to the conduct of large randomized trials. Group C, 1 of the 3 discussion groups, examined recurrent ovarian cancer, and we report the consensus reached regarding 4 questions. These included the following: (1) What is the role of cytoreductive surgery for recurrent ovarian cancer? (2) How do we define distinct patient populations in need of specific therapeutic approaches? (3) Should end points for trials with recurrent disease vary from those of first-line trials? (4) Is CA-125 progression alone sufficient for entry/eligibility into clinical trials?

KW - Clinical trials

KW - Ovarian cancer

KW - Recurrent

UR - http://www.scopus.com/inward/record.url?scp=80051910971&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80051910971&partnerID=8YFLogxK

U2 - 10.1097/IGC.0b013e31821bb8aa

DO - 10.1097/IGC.0b013e31821bb8aa

M3 - Article

C2 - 21543939

AN - SCOPUS:80051910971

VL - 21

SP - 771

EP - 775

JO - International Journal of Gynecological Cancer

JF - International Journal of Gynecological Cancer

SN - 1048-891X

IS - 4

ER -